MX2009001896A - Inhibicion medida por arn-i de gremlin para el tratamiento de condiciones relacionadas con iop. - Google Patents

Inhibicion medida por arn-i de gremlin para el tratamiento de condiciones relacionadas con iop.

Info

Publication number
MX2009001896A
MX2009001896A MX2009001896A MX2009001896A MX2009001896A MX 2009001896 A MX2009001896 A MX 2009001896A MX 2009001896 A MX2009001896 A MX 2009001896A MX 2009001896 A MX2009001896 A MX 2009001896A MX 2009001896 A MX2009001896 A MX 2009001896A
Authority
MX
Mexico
Prior art keywords
gremlin
related conditions
iop
rnai
treatment
Prior art date
Application number
MX2009001896A
Other languages
English (en)
Spanish (es)
Inventor
Abbot F Clark
Jon E Chatterton
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of MX2009001896A publication Critical patent/MX2009001896A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2009001896A 2006-08-24 2007-08-24 Inhibicion medida por arn-i de gremlin para el tratamiento de condiciones relacionadas con iop. MX2009001896A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83982606P 2006-08-24 2006-08-24
PCT/US2007/076776 WO2008024983A2 (en) 2006-08-24 2007-08-24 Rnai-mediated inhibition of gremlin for treatment of iop-related conditions

Publications (1)

Publication Number Publication Date
MX2009001896A true MX2009001896A (es) 2009-04-17

Family

ID=39032079

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009001896A MX2009001896A (es) 2006-08-24 2007-08-24 Inhibicion medida por arn-i de gremlin para el tratamiento de condiciones relacionadas con iop.

Country Status (11)

Country Link
US (3) US20080051361A1 (enExample)
EP (1) EP2059597A2 (enExample)
JP (1) JP2010501188A (enExample)
KR (1) KR20090042297A (enExample)
CN (2) CN102743767A (enExample)
AU (1) AU2007286545A1 (enExample)
BR (1) BRPI0715821A2 (enExample)
CA (1) CA2659464A1 (enExample)
MX (1) MX2009001896A (enExample)
WO (1) WO2008024983A2 (enExample)
ZA (1) ZA200900553B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006006948A2 (en) * 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
GB0708662D0 (en) * 2007-05-04 2007-06-13 Galapagos Nv shRNA sequences
WO2009046059A1 (en) * 2007-10-01 2009-04-09 Alcon Research, Ltd. Self complementary aav-mediated delivery of interfering rna molecules to treat or prevent ocular disorders
BRPI0802525A2 (pt) 2008-07-11 2010-03-09 Kiyoshi Hashiba endoscópio cirúrgico
US9745574B2 (en) 2009-02-04 2017-08-29 Rxi Pharmaceuticals Corporation RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
US8778904B2 (en) * 2009-12-09 2014-07-15 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the CNS
CN103200945B (zh) 2010-03-24 2016-07-06 雷克西制药公司 眼部症候中的rna干扰
RU2599449C1 (ru) 2011-12-15 2016-10-10 Байонир Корпорейшн Новые конъюгаты олигонуклеотидов и их применение
KR101722948B1 (ko) 2012-01-05 2017-04-04 (주)바이오니아 리간드가 결합된 이중나선 올리고 ｒｎａ 구조체 및 그 제조방법
JP6060178B2 (ja) 2012-01-05 2017-01-18 バイオニア コーポレーションＢｉｏｎｅｅｒ Ｃｏｒｐｏｒａｔｉｏｎ 高効率のナノ粒子型二本鎖オリゴｒｎａ構造体およびその製造方法
JP5906327B2 (ja) 2012-01-18 2016-04-20 バイオニア コーポレーションＢｉｏｎｅｅｒ Ｃｏｒｐｏｒａｔｉｏｎ 磁性ナノ粒子−ＳＡＭｉＲＮＡ複合体およびその製造方法
TR201905395T4 (tr) * 2012-03-15 2019-05-21 Hyun Kee Kim Anti-gremlin-1 antikoru.
IN2015DN02699A (enExample) * 2012-09-05 2015-09-04 Sylentis Sau
GB201215857D0 (en) * 2012-09-05 2012-10-24 Sylentis Sau siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
US10030243B2 (en) 2013-07-05 2018-07-24 Bioneer Corporation Nanoparticle type oligonucleotide structure having high efficiency and method for preparing same
WO2015132303A1 (en) 2014-03-04 2015-09-11 Sylentis Sau Sirnas and their use in methods and compositions for the treatment and/or prevention of eye conditions
CA2947270A1 (en) 2014-04-28 2015-11-05 Rxi Pharmaceuticals Corporation Methods for treating cancer using nucleic acids targeting mdm2 or mycn
JP2017200928A (ja) * 2017-05-31 2017-11-09 シレンティス・エセ・ア・ウ ｓｉＲＮＡならびに眼の状態の処置および／または予防のための方法および組成物におけるその使用
CN106978509B (zh) * 2017-06-07 2018-10-26 中南大学湘雅二医院 青光眼诊断分子标记物lncRNAs ENST00000607393、试剂盒及应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1685055A (zh) * 2001-10-31 2005-10-19 爱尔康公司 骨形态发生蛋白(bmp)、bmp受体和bmp结合蛋白及它们在诊断和治疗青光眼中的用途
US20040138163A1 (en) * 2002-05-29 2004-07-15 Mcswiggen James RNA interference mediated inhibition of vascular edothelial growth factor and vascular edothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
WO2006006948A2 (en) * 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US20060141049A1 (en) * 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
TW200639253A (en) * 2005-02-01 2006-11-16 Alcon Inc RNAi-mediated inhibition of ocular targets

Also Published As

Publication number Publication date
CA2659464A1 (en) 2008-02-28
WO2008024983A3 (en) 2008-10-09
BRPI0715821A2 (pt) 2013-07-23
AU2007286545A1 (en) 2008-02-28
CN101517081A (zh) 2009-08-26
US20120077864A1 (en) 2012-03-29
EP2059597A2 (en) 2009-05-20
JP2010501188A (ja) 2010-01-21
US20080051361A1 (en) 2008-02-28
WO2008024983A2 (en) 2008-02-28
ZA200900553B (en) 2010-04-28
US20100305193A1 (en) 2010-12-02
KR20090042297A (ko) 2009-04-29
CN102743767A (zh) 2012-10-24

Similar Documents

Publication Publication Date Title
MX2009001896A (es) Inhibicion medida por arn-i de gremlin para el tratamiento de condiciones relacionadas con iop.
WO2006083945A3 (en) Rnai-mediated inhibition of ocular targets
WO2007076367A3 (en) Rnai-mediated inhibition of rho kinase for treatment of ocular hypertension / glaucoma
WO2008067382A3 (en) Rnai-mediated inhibition of aquaporin 4 for treatment of iop-related conditions
WO2005068421A8 (en) Prostaglandin nitrooxyderivatives
WO2008070728A3 (en) Treatment for dry eye using testosterone and progestagen
SI2306977T1 (sl) Postopek in sestavek za zdravljenje oäśesne hipertenzije in glavkoma
EP3542629A3 (en) Dithiol compounds, derivatives, and uses therefor
WO2007076360A8 (en) (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)- pyrazines for treating rho kinase-mediated diseases and conditions
WO2006021817A3 (en) Treatment of eye disorders characterized by an elevated introacular pressure by sirnas
IL186598A0 (en) Composition and method for the treatment or prevention of glaucoma and ocular hypertension
MX2007010608A (es) Inhibicion mediada por i-arn de proteina i relacionada con frizzled para tratamiento de glaucoma.
WO2009098458A3 (en) Difluorobiphenylamide derivatives for the treatment of ocular hypertension
WO2008067373A3 (en) RNAi-MEDIATED INHIBITION OF AQUAPORIN 1 FOR TREATMENT OF IOP-RELATED CONDITIONS
WO2007121347A3 (en) Rnai-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions
WO2007127711A3 (en) Abnormal cannabidiols as agents for lowering intraocular pressure
WO2007000641A3 (en) Prostaglandin derivatives
WO2007146136A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2009091764A3 (en) Beta-lactams for the treatment of glaucoma, ocular hypertension, baldness and hair loss
WO2007121156A3 (en) Rnai-mediated inhibition of histamine receptor h1-related conditions
WO2012024419A3 (en) Bradykinin receptor agonists and uses thereof to treat ocular hypertension and glaucoma
WO2006007227A3 (en) Abnormal cannabidiols for lowering intraocular pressure
WO2008030390A3 (en) Ophthalmic compositions for treating ocular hypertension
ZA200706084B (en) RNAI-mediated inhibition of ocular hypertension targets
WO2008092143A3 (en) Rnai-mediated inhibition of aquaporin 4 for treatment of ocular neovascularization

Legal Events

Date Code Title Description
FG Grant or registration